OPEN Health
Dr. Elisabeth Fenwick - Chief Scientific Officer
Dr. Elisabeth Fenwick is Chief Scientific Officer at OPEN Health. Liz provides scientific and strategic support to health economic projects globally, having worked in the field for over 20 years. Her core expertise is in economic modeling (including early modeling), uncertainty analysis, and value of information.
An article written by Dr. Elisabeth Fenwick
Novel Oncology Therapies Require Innovative Methods in Oncology Modeling
Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.
Health technology assessment (HTA) agencies have long required evidence of long-term survival and lifetime estimates of quality of life before they will approve new treatments. Health economics and outcomes research analysts have relied on standard parametric models to extrapolate overall survival rates from clinical trial data to estimate quality of life.
This traditional approach identifies the statistical models that best fit the available data and then uses these models to predict outcomes over the lifetime. It worked well for traditional cancer treatments, including chemotherapy. However, many new oncology drugs have a different mechanism of action—including the possibility of delayed and prolonged response to treatment and, potentially, cure—which may not be accurately represented by these traditional models.
Novel Approaches to Plugging Data Gaps: Pharmacometric Models and Beyond
Watch the webinar if you would like to:
- Understand the common data gaps in health economic (HE) analyses and the need for bespoke modeling solutions
- Consider an application of a PM model used for a PE analysis to fill a data gap relating to clinical outcomes
- Explore further methods and opportunities to navigate and fill data gaps for HE analyses in different stages of drug delivery